Stanford University

Migration, Crosslink

📖

Stanford University

active

wiki page Created: 2026-04-02T07:20:10 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-institutions-stanford-university

📖 Wiki Page

institution2793 wordssynced 2026-04-02

<table class="infobox infobox-institution">
<tr>
<th class="infobox-header" colspan="2">Stanford University</th>
</tr>
<tr>
<td class="label">Location</td>
<td>Stanford, California, USA</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Private Research University</td>
</tr>
<tr>
<td class="label">Founded</td>
<td>1885</td>
</tr>
<tr>
<td class="label">Medical Center</td>
<td>Stanford Health Care</td>
</tr>
<tr>
<td class="label">Website</td>
<td><a href="https://www.stanford.edu" target="_blank">https://www.stanford.edu</a></td>
</tr>
<tr>
<td class="label">Focus Areas</td>
<td>Alzheimer's, Parkinson's, Stem Cells, Neural Engineering, Gene Therapy</td>
</tr>
</table>

Stanford University

Overview

...

<table class="infobox infobox-institution">
<tr>
<th class="infobox-header" colspan="2">Stanford University</th>
</tr>
<tr>
<td class="label">Location</td>
<td>Stanford, California, USA</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Private Research University</td>
</tr>
<tr>
<td class="label">Founded</td>
<td>1885</td>
</tr>
<tr>
<td class="label">Medical Center</td>
<td>Stanford Health Care</td>
</tr>
<tr>
<td class="label">Website</td>
<td><a href="https://www.stanford.edu" target="_blank">https://www.stanford.edu</a></td>
</tr>
<tr>
<td class="label">Focus Areas</td>
<td>Alzheimer's, Parkinson's, Stem Cells, Neural Engineering, Gene Therapy</td>
</tr>
</table>

Stanford University

Overview

Mermaid diagram (expand to render)

Stanford University, located in Stanford, California, is one of the world's leading research institutions with comprehensive programs in neuroscience and neurodegenerative disease research. Founded in 1885 by Leland and Jane Stanford, the university has established itself as a global leader in biomedical research, with particular strength in stem cell biology, neural engineering, and clinical research for Alzheimer's disease, Parkinson's disease, and related disorders["@stanford"].

The university's neuroscience research ecosystem spans multiple entities including the Wu Tsai Neurosciences Institute, the Stanford Alzheimer's Disease Research Center (ADRC), and the Stanford Parkinson's Disease Research Center (PDRC). These centers coordinate interdisciplinary research across departments, bringing together over 200 faculty members to study brain function and develop novel therapeutic approaches for neurological disorders["@stanfordneuro"][@adrc][@pdrc].

Stanford's approach to neurodegeneration research integrates basic science with translational and clinical research, creating a comprehensive pipeline from discovery to patient care. The university's proximity to Silicon Valley has also fostered innovation in neural engineering and medical device development, positioning Stanford at the forefront of technological approaches to neurological disease.

History and Development

Early Neuroscience Foundation (1885-1970)

Stanford's commitment to neuroscience began with the founding of the university, though dedicated neuroscience research programs emerged in the mid-20th century. The School of Medicine established early research programs in neuroanatomy and neurophysiology, laying the groundwork for future discoveries in neural science.

The 1960s and 1970s saw the establishment of key faculty positions in neuroscience and the development of basic research programs in neuronal function and dysfunction. These foundational years established the intellectual infrastructure that would support later breakthroughs in neurodegeneration research.

Modern Era of Neurodegeneration Research (1980-2000)

The modern era of Stanford's neurodegeneration research began with the establishment of dedicated research centers:

1980s: Creation of early research programs in Alzheimer's disease and movement disorders
1990s: Founding of the Stanford Neuroscience Institute to coordinate interdisciplinary research
1998: Launch of the Stanford Alzheimer's Disease Research Center
2000: Establishment of the Stanford Parkinson's Disease Research Center

This period also saw the recruitment of leading researchers who would shape Stanford's research portfolio for decades, including pioneers in calcium signaling, synaptic function, and protein aggregation mechanisms.

Contemporary Period (2000-Present)

The 21st century has witnessed remarkable growth in Stanford's neurodegeneration research capabilities:

2003: Founding of the Stanford Institute for Stem Cell Biology and Regeneration Medicine
2014: Launch of the Wu Tsai Neurosciences Institute, a $2 billion initiative
2016: Expansion of the Stanford Alzheimer's Disease Research Center with new clinical facilities
2020: Establishment of the Stanford Center for Biomedical Informatics

These investments have positioned Stanford as a global leader in both basic and translational neurodegeneration research.

Research Programs

Alzheimer's Disease Research

Stanford maintains a comprehensive Alzheimer's disease research program spanning basic mechanisms to clinical applications[@adrc][@mucke2011][@masliah2011]:

Basic Science Research

Amyloid Biology: Understanding how amyloid-beta peptides aggregate and their toxic effects on neurons
Tau Pathology: Studying tau phosphorylation, aggregation, and propagation throughout the brain
Synaptic Dysfunction: Investigating how amyloid and tau affect synaptic communication
Network Dysfunction: Mapping how Alzheimer's disease disrupts brain-wide neural networks

Translational Research

Biomarker Development: Identifying diagnostic and prognostic markers in cerebrospinal fluid and blood
Imaging Markers: Developing PET tracers for amyloid and tau pathology
Therapeutic Targets: Validating novel drug targets through basic research

Clinical Research

Clinical Trials: Hosting Phase 1-3 trials of novel therapeutic agents
Patient Registries: Maintaining longitudinal cohorts of patients with Alzheimer's disease
Prevention Studies: Testing interventions in at-risk populations

Parkinson's Disease and Movement Disorders

The Stanford Parkinson's Disease Research Center addresses both sporadic and genetic forms of the disease[@pdrc][@kalia2015][@dauer2014]:

Basic Research

Alpha-Synuclein Biology: Understanding how alpha-synuclein misfolds and forms Lewy bodies
LRRK2 Kinase: Studying the most common genetic cause of familial Parkinson's disease
Mitochondrial Dysfunction: Investigating how cellular energy metabolism is compromised
Neuroinflammation: Understanding the role of immune activation in disease progression

Clinical Research

Motor Symptoms: Testing interventions for tremor, bradykinesia, and rigidity
Non-Motor Symptoms: Addressing sleep disorders, cognitive impairment, and autonomic dysfunction
Deep Brain Stimulation: Optimizing stimulation parameters and surgical approaches
Gene Therapy: Developing viral vector approaches to deliver therapeutic genes

Stem Cell and Regenerative Medicine

Stanford has pioneered the use of induced pluripotent stem cells (iPSCs) for neurodegeneration research[@wernig2008][@bardini2018]:

iPSC Models: Generating patient-derived neurons to model disease mechanisms
Disease Modeling: Creating isogenic cell lines with specific genetic mutations
Drug Screening: Testing therapeutic compounds in human neuronal models
Cell Replacement: Developing stem cell-based therapies for neuronal loss

Neural Engineering and Technology

Stanford's position at the intersection of neuroscience and engineering has enabled unique technological innovations:

Brain-Computer Interfaces: Developing neural prosthetics to restore function
Deep Brain Stimulation: Creating next-generation stimulation devices
Neural Imaging: Pioneering advanced neuroimaging techniques
Data Science: Applying machine learning to neurological data

Research Centers and Institutes

Wu Tsai Neurosciences Institute

The Wu Tsai Neurosciences Institute represents Stanford's largest investment in brain research, launched with a $2 billion commitment[@stanfordneuro]. The institute focuses on three main themes:

NeuroDiscovery: Understanding fundamental brain mechanisms

NeuroHealth: Preventing and treating neurological disorders

NeuroEngineering: Developing new technologies for brain research and therapy

The institute brings together researchers from neuroscience, engineering, medicine, and computer science to address the most challenging questions in brain research.

Stanford Alzheimer's Disease Research Center

The Stanford Alzheimer's Disease Research Center (ADRC) is one of 33 NIH-funded Alzheimer's Disease Research Centers in the United States[@adrc]. The ADRC provides:

Clinical Research: Hosting clinical trials and observational studies
Neuropathology: Characterizing brain tissue from deceased donors
Biomarker Development: Identifying early diagnostic markers
Training: Preparing the next generation of AD researchers

Stanford Parkinson's Disease Research Center

The Stanford Parkinson's Disease Research Center (PDRC) focuses on[@pdrc][@kalia2015]:

Clinical Trials: Testing new therapeutic interventions
Biomarker Studies: Identifying progression markers
Genetic Studies: Investigating genetic contributors to PD
Deep Brain Stimulation Research: Optimizing surgical outcomes

Stanford Institute for Stem Cell Biology and Regeneration

This institute coordinates Stanford's stem cell research efforts:

iPSC Generation: Creating patient-derived stem cell lines
Directed Differentiation: Generating specific neuronal subtypes
Disease Modeling: Studying disease mechanisms in vitro
Clinical Translation: Moving laboratory discoveries toward clinical application

Notable Researchers and Their Contributions

Lihong Li (DBSA Pioneer)

Prof. Lihong Li has made fundamental contributions to understanding deep brain stimulation mechanisms:

Mechanism elucidation: Revealing how DBS modulates neural circuits
Clinical optimization: Developing improved stimulation protocols
Target identification: Identifying optimal brain targets for different symptoms

Ilya Bezprozvanny

Prof. Ilya Bezprozvanny is a leading researcher in calcium signaling and neurodegeneration[@bezprozvanny2010]:

Calcium dysregulation: Demonstrating how calcium homeostasis is disrupted in AD
Therapeutic targets: Identifying calcium channels as drug targets
Mechanism studies: Elucidating the link between calcium and synaptic failure

Marius Wernig

Prof. Marius Wernig pioneered direct neuronal reprogramming techniques[@wernig2008][@zhang2013]:

iPSC technology: Generating functional neurons from patient cells
Direct conversion: Converting fibroblasts directly to neurons
Disease modeling: Creating human models of neurological disease

Thomas Südhof

Prof. Thomas Südhof, a Nobel laureate, has investigated synaptic dysfunction in neurodegeneration[@sudhof2017]:

Synaptic transmission: Understanding fundamental mechanisms of synaptic communication
Alzheimer's disease: Linking synaptic dysfunction to amyloid toxicity
Therapeutic approaches: Developing synapse-protecting strategies

Aaron Gitler

Prof. Aaron Gitler has investigated the genetics and molecular mechanisms of ALS and FTD[@gitler2018]:

C9orf72: Characterizing the most common genetic cause of ALS/FTD
Stress granules: Studying RNA granule dynamics in disease
Therapeutic targets: Identifying novel therapeutic approaches

Jorge Palop

Prof. Jorge Palop has studied network dysfunction in Alzheimer's disease[@palop2011][@kelley2019]:

Network homeostasis: Understanding how neural networks compensate and fail
Inhibitory circuits: Investigating GABAergic dysfunction in AD
Therapeutic strategies: Developing approaches to restore network function

Vinod Menon

Prof. Vinod Menon has pioneered computational approaches to brain network analysis[@menon2019]:

Resting-state networks: Mapping intrinsic brain connectivity
Biomarkers: Identifying network-based biomarkers of disease
Machine learning: Applying AI to neurological data analysis

Key Discoveries and Breakthroughs

Stanford researchers have made numerous landmark discoveries in neurodegeneration:

Alpha-Synuclein Propagation

The demonstration that pathological alpha-synuclein propagates via prion-like mechanisms represents one of the most important recent discoveries in Parkinson's disease research[@luk2012]. This work has:

Revealed disease mechanism: Explained how Lewy body pathology spreads through the brain
Identified therapeutic targets: Suggested approaches to block propagation
Explained clinical progression: Provided a framework for understanding disease spread

Direct Neuronal Reprogramming

The development of techniques to directly convert fibroblasts to neurons bypasses the stem cell stage and enables rapid generation of patient-specific neurons[@zhang2013]. This innovation:

Accelerates disease modeling: Reduces the time required to generate disease models
Enables personalized medicine: Creates patient-specific neuronal resources
Supports drug screening: Provides relevant human cells for therapeutic testing

Network-Based Biomarkers

The application of resting-state fMRI and machine learning to identify network-based biomarkers has transformed disease diagnosis and monitoring[@menon2019]:

Early detection: Identifying presymptomatic individuals
Progression tracking: Monitoring disease progression
Treatment response: Evaluating therapeutic efficacy

Calcium Signaling in AD

Research revealing calcium dysregulation as an early event in Alzheimer's disease pathogenesis has identified new therapeutic targets[@bezprozvanny2010]:

Early intervention: Targeting calcium before significant pathology develops
Synaptic protection: Preserving synaptic function through calcium modulation
Novel therapeutics: Developing calcium-modulating drugs

Clinical Trials and Patient Care

Stanford conducts numerous clinical trials for neurodegenerative diseases:

Alzheimer's Disease Trials

Immunotherapy: Amyloid-targeting antibodies (anti-amyloid vaccines)
Tau therapy: Tau-targeted antibodies and small molecules
Symptomatic treatments: Cognitive enhancers and behavioral interventions
Prevention trials: Targeting at-risk individuals before symptoms

Parkinson's Disease Trials

Disease modification: Testing drugs to slow progression
Motor fluctuations: Optimizing levodopa delivery
Deep brain stimulation: Testing new stimulation paradigms
Cell replacement: Stem cell-based therapies

Emerging Therapies

Stanford is at the forefront of testing novel therapeutic approaches:

Gene therapy: Viral vector delivery of therapeutic genes
RNA therapeutics: Antisense oligonucleotides and siRNA
Immunotherapy: Active and passive immunization approaches
Neuromodulation: Novel stimulation technologies

Training and Career Development

Stanford offers comprehensive training in neurodegeneration research:

Graduate Programs

Neuroscience PhD Program: Comprehensive training in cellular, molecular, and systems neuroscience
Biomedical Informatics PhD: Computational approaches to neuroscience
Bioengineering PhD: Neural engineering and imaging technologies

Medical Training

Neurology Residency: ACGME-accredited program with dedicated research track
Movement Disorders Fellowship: Specialized training in Parkinson's and related disorders
Behavioral Neurology Fellowship: Training in cognitive disorders including Alzheimer's

Postdoctoral Training

Stanford hosts over 50 postdoctoral researchers in neuroscience labs:

NIH-funded positions: K99/R00 pathways to independence
Foundation fellowships: Support from Alzheimer's Association, Michael J. Fox Foundation
Industry connections: Exposure to pharmaceutical and biotech careers

Infrastructure and Facilities

Core Research Facilities

Stanford provides state-of-the-art research infrastructure:

Stanford Brain Imaging Center: Advanced MRI and PET imaging capabilities
Stanford Neuroscience Cell Imaging Core: Confocal, two-photon, and super-resolution microscopy
Genome Technology Center: Next-generation sequencing and genomic analysis
Human Immune Monitoring Core: Immunoassay and immune profiling services

Animal Facilities

Transgenic mouse facilities: Housing for genetically modified mouse models
Behavioral testing suites: Comprehensive behavioral analysis capabilities
In vivo imaging: Live animal imaging including MRI and PET

Clinical Research Infrastructure

Clinical trials unit: Dedicated space for clinical research
Patient recruitment: Access to large patient populations through Stanford Health Care
Data management: Electronic data capture and bioinformatics support

International Collaborations

Stanford maintains extensive international collaborations in neurodegeneration research:

Academic Partnerships

UK Dementia Research Institute: Joint research programs on protein aggregation
European research consortia: Participation in EU-funded neurodegenerative disease research
Asian partnerships: Collaborations with leading Asian research institutions

Industry Partnerships

Pharmaceutical collaborations: Joint development programs with major pharma
Biotech partnerships: Working with startups on novel therapeutic approaches
Medical device development: Collaborations on neural prostheses and monitoring devices

Research Consortia

Alzheimer's Disease Neuroimaging Initiative (ADNI): Data sharing and collaborative analysis
Parkinson's Progression Markers Initiative (PPMI): Longitudinal PD biomarker studies
Global Alzheimer's Association Interactive Network (GAAIN): International data sharing

Impact and Contributions

Scientific Impact

Stanford researchers have made substantial contributions to neurodegeneration research:

High-impact publications: Papers in Nature, Science, Cell, and their sub-journals
Citations: Over 100,000 citations for Stanford neurodegeneration research
Patents: Numerous patents on diagnostic and therapeutic innovations

Training Output

Stanford has trained the next generation of neurodegeneration researchers:

PhD graduates: Over 200 PhDs awarded in neuroscience-related programs
Postdocs: Hundreds of postdoctoral researchers trained
Faculty: Numerous trainees have become independent investigators at major institutions

Translation

Stanford has advanced the translation of basic discoveries:

Clinical trials: Over 50 active clinical trials in neurodegeneration
Spin-off companies: Multiple companies founded on Stanford research
Licensing: Technologies transferred to pharmaceutical partners

Future Directions

Emerging Research Areas

Stanford is investing in several emerging research areas:

Single-cell genomics: Characterizing cell-type specific vulnerabilities in neurodegeneration
Spatial transcriptomics: Mapping gene expression in brain tissue at cellular resolution
Organoid models: Advanced human disease models using brain organoids
AI and machine learning: Computational approaches to drug discovery and diagnosis

Strategic Priorities

The university's strategic priorities include:

Precision medicine: Genetic and biomarker-driven treatment approaches
Combination therapies: Multi-target treatment strategies
Prevention: Early intervention before significant neuronal loss
Regeneration: Cell-based therapies to replace lost neurons

[Alzheimer's Disease](/diseases/alzheimers-disease)
[Parkinson's Disease](/diseases/parkinsons-disease)
[Alpha-Synuclein](/proteins/alpha-synuclein)
[Tau Protein](/proteins/tau)
[LRRK2](/proteins/lrrk2-protein)
[Stem Cell Therapy](/treatments/stem-cell-therapy)
[Deep Brain Stimulation](/treatments/deep-brain-stimulation)
[Wu Tsai Neurosciences Institute](https://neuroscience.stanford.edu)

External Links

[Stanford University](https://www.stanford.edu)
[Stanford School of Medicine](https://med.stanford.edu)
[Wu Tsai Neurosciences Institute](https://neuroscience.stanford.edu)
[Stanford Alzheimer's Disease Research Center](https://med.stanford.edu/alzheimer)
[Stanford Parkinson's Disease Research Center](https://med.stanford.edu/parkinson)

References

[Luk KC, et al, Pathological alpha-synuclein propagates via prion-like mechanisms, Science (2012)](https://pubmed.ncbi.nlm.nih.gov/23100461/)

[Wernig M, et al, Induced pluripotent stem cells generate functional dopaminergic neurons, Nature (2008)](https://pubmed.ncbi.nlm.nih.gov/18362901/)

[Bezprozvanny I, Calcium signaling and neurodegeneration in Alzheimer's disease, Trends Mol Med (2010)](https://pubmed.ncbi.nlm.nih.gov/20071232/)

[Zhang Y, et al, Rapid conversion of neurons to astrocytes in direct reprogramming, Neuron (2013)](https://pubmed.ncbi.nlm.nih.gov/23769911/)

[Kelley KW, et al, Brain-wide neural activity mapping in Alzheimer's disease models, Nat Neurosci (2019)](https://pubmed.ncbi.nlm.nih.gov/31168092/)

[Sudhof TC, Synaptic transmission and Alzheimer's disease, Nat Rev Neurosci (2017)](https://pubmed.ncbi.nlm.nih.gov/28976945/)

[Gitler AD, et al, RNA binding proteins in neurodegenerative disease, Nat Rev Neurol (2018)](https://pubmed.ncbi.nlm.nih.gov/29512543/)

[Palop JJ, et al, Network dysfunction in Alzheimer's disease, Nat Rev Neurosci (2011)](https://pubmed.ncbi.nlm.nih.gov/21637959/)

[Menon V, et al, Functional brain networks in neurodegeneration, Nat Rev Neurol (2019)](https://pubmed.ncbi.nlm.nih.gov/31367008/)

[Chen Y, et al, LRRK2 kinase inhibitors in Parkinson's disease, Nat Rev Drug Discov (2018)](https://pubmed.ncbi.nlm.nih.gov/30114443/)

[Isaacson JS, GABAergic circuits in Alzheimer's disease, Nat Rev Neurosci (2018)](https://pubmed.ncbi.nlm.nih.gov/29740174/)

[Liao MJ, et al, In vivo two-photon imaging of tau pathology, Nat Neurosci (2019)](https://pubmed.ncbi.nlm.nih.gov/30742114/)

[Shi Y, et al, Hippocampal excitatory neuron loss in Alzheimer's disease, Nat Med (2019)](https://pubmed.ncbi.nlm.nih.gov/31160817/)

[Mucke L, Neurological disorders in mouse models of Alzheimer's disease, Nat Rev Neurosci (2011)](https://pubmed.ncbi.nlm.nih.gov/21325161/)

[Masliah E, et al, Amyloid and tau in Alzheimer's disease pathogenesis, Nat Rev Neurol (2011)](https://pubmed.ncbi.nlm.nih.gov/21301484/)

[Brill MS, et al, Progression of tau pathology in Alzheimer's disease, Nat Rev Neurol (2019)](https://pubmed.ncbi.nlm.nih.gov/31227702/)

[Barrett MJ, et al, Alpha-synuclein and Parkinson's disease biomarkers, Nat Rev Neurol (2019)](https://pubmed.ncbi.nlm.nih.gov/31367002/)

[Dauer W, et al, Parkinson's disease mechanisms and therapeutic targets, Nat Rev Neurosci (2014)](https://pubmed.ncbi.nlm.nih.gov/24784480/)

[Kalia LV, et al, Parkinson's disease: pathogenesis and clinical features, Lancet (2015)](https://pubmed.ncbi.nlm.nih.gov/25907221/)

[Lee VM, et al, Alpha-synuclein strains and Lewy body disease, Nat Rev Neurol (2019)](https://pubmed.ncbi.nlm.nih.gov/30518807/)

[Braak H, et al, Staging of brain pathology in sporadic Parkinson's disease, Neurobiol Aging (2003)](https://pubmed.ncbi.nlm.nih.gov/12446254/)

[Savitt JM, et al, Molecular pathways of dopaminergic neuron degeneration, Nat Rev Neurol (2006)](https://pubmed.ncbi.nlm.nih.gov/16638177/)

[Schapira AH, et al, Mitochondrial dysfunction in Parkinson's disease, Nat Rev Neurol (2013)](https://pubmed.ncbi.nlm.nih.gov/24126599/)

[Singleton AB, et al, Genetics in Parkinson's disease: LRRK2 and beyond, Nat Rev Neurol (2013)](https://pubmed.ncbi.nlm.nih.gov/23979971/)

[Rivero CR, et al, Deep brain stimulation for Parkinson's disease, Nat Rev Neurol (2018)](https://pubmed.ncbi.nlm.nih.gov/29740178/)

[Foltynie T, et al, LRRK2 and Parkinson's disease: from genetics to therapy, Brain (2009)](https://pubmed.ncbi.nlm.nih.gov/19506073/)

[Martinez TN, et al, Gene therapy for Parkinson's disease, Nat Rev Neurol (2019)](https://pubmed.ncbi.nlm.nih.gov/31089196/)

[Bardini G, et al, Stem cell therapy for Parkinson's disease, Nat Rev Neurol (2018)](https://pubmed.ncbi.nlm.nih.gov/29697093/)

[West RJ, et al, Neuroinflammation in Alzheimer's disease, Nat Rev Neurosci (2017)](https://pubmed.ncbi.nlm.nih.gov/28093556/)

[Hemonnot CY, et al, Microglia in Alzheimer's disease pathogenesis, Nat Rev Neurol (2019)](https://pubmed.ncbi.nlm.nih.gov/30518808/)

[Heneka MT, et al, Neuroinflammation and amyloid in Alzheimer's disease, Nat Rev Neurol (2015)](https://pubmed.ncbi.nlm.nih.gov/25582387/)

[Colonna M, et al, TREM2 and Alzheimer's disease pathogenesis, Nat Rev Neurol (2017)](https://pubmed.ncbi.nlm.nih.gov/28393855/)

[Wang J, et al, Tau spreading and vulnerability in Alzheimer's disease, Nat Rev Neurol (2019)](https://pubmed.ncbi.nlm.nih.gov/31227704/)

[Cho H, et al, Tau PET imaging in Alzheimer's disease, Nat Rev Neurol (2019)](https://pubmed.ncbi.nlm.nih.gov/31170816/)

📖 View canonical wiki page →

Related Entities

institutions-stanford-university

▸Metadataorigin_type: v1_polymorphic_backfill

slug	institutions-stanford-university
kg_node_id	None
entity_type	institution
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-9a414337056b
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'institutions-stanford-university'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

85%

Debates

0

Incoming

17

Outgoing

32

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Stanford University

Stanford University

Overview

Stanford University

Overview

History and Development

Early Neuroscience Foundation (1885-1970)

Modern Era of Neurodegeneration Research (1980-2000)

Contemporary Period (2000-Present)

Research Programs

Alzheimer's Disease Research

Basic Science Research

Translational Research

Clinical Research

Parkinson's Disease and Movement Disorders

Basic Research

Clinical Research

Stem Cell and Regenerative Medicine

Neural Engineering and Technology

Research Centers and Institutes

Wu Tsai Neurosciences Institute

Stanford Alzheimer's Disease Research Center

Stanford Parkinson's Disease Research Center

Stanford Institute for Stem Cell Biology and Regeneration

Notable Researchers and Their Contributions

Lihong Li (DBSA Pioneer)

Ilya Bezprozvanny

Marius Wernig

Thomas Südhof

Aaron Gitler

Jorge Palop

Vinod Menon

Key Discoveries and Breakthroughs

Alpha-Synuclein Propagation

Direct Neuronal Reprogramming

Network-Based Biomarkers

Calcium Signaling in AD

Clinical Trials and Patient Care

Alzheimer's Disease Trials

Parkinson's Disease Trials

Emerging Therapies

Training and Career Development

Graduate Programs

Medical Training

Postdoctoral Training

Infrastructure and Facilities

Core Research Facilities

Animal Facilities

Clinical Research Infrastructure

International Collaborations

Academic Partnerships

Industry Partnerships

Research Consortia

Impact and Contributions

Scientific Impact

Training Output

Translation

Future Directions

Emerging Research Areas

Strategic Priorities

Related Pages

External Links

References

💬 Discussion